Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-103
- Development stage
- Phase 2
- Lead developer
- Scilex Holding
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical, Transdermal
01
Overview
SP-103 is a next-generation, triple-strength topical system containing 5.4% lidocaine, developed as a non-aqueous adhesive patch for the treatment of acute low back pain (LBP) and other musculoskeletal pain disorders. It is designed to deliver three times the amount of lidocaine per application area compared to ZTlido (1.8%), using the same adhesive drug delivery technology. The increased drug load aims to provide enhanced localized analgesia without increasing systemic toxicity or application site reactions, as demonstrated in Phase 2 clinical trials. SP-103 has received Fast Track designation from the FDA for low back pain and is being developed by Scilex Holding Company as a non-opioid alternative for acute and chronic pain management[2][3][6][8].
- Other names
- lidocaine topical system 5.4%triple-strength formulation of ZTlido
02
Targets
NaV alpha (Voltage-gated sodium channel alpha subunit family)
Beyond the preview
Go deeper on SP-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-103.